Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures
Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms
Read More 6 minute read Healthcare Industry News Pharma Industry News Can Allurion Technologies reset investor confidence with FDA momentum and a debt-free strategy? Allurion Technologies aims to bounce back with FDA milestones, a debt-free strategy, and new capital. Will this turnaround move the stock in 2025? bySrinathNovember 11, 2025